666 related articles for article (PubMed ID: 15801998)
1. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
[TBL] [Abstract][Full Text] [Related]
2. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK.
Guest JF; Ruiz FJ; Greener MJ; Trotman IF
Eur J Cancer Care (Engl); 2006 Mar; 15(1):65-73. PubMed ID: 16441679
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
6. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F
Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.
Greiner W; Lehmann K; Earnshaw S; Bug C; Sabatowski R
Eur J Health Econ; 2006 Dec; 7(4):290-6. PubMed ID: 16983521
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
9. Resource consumption and costs of treating pain in patients affected by cancer in a district of northeast Italy.
Roggeri D; Saramin C; Terrazzani G; Zusso M; Giusti P; Chinellato A
Pharmacol Res; 2007 Oct; 56(4):329-34. PubMed ID: 17851088
[TBL] [Abstract][Full Text] [Related]
10. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
[TBL] [Abstract][Full Text] [Related]
11. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.
Payne R; Mathias SD; Pasta DJ; Wanke LA; Williams R; Mahmoud R
J Clin Oncol; 1998 Apr; 16(4):1588-93. PubMed ID: 9552070
[TBL] [Abstract][Full Text] [Related]
12. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
Botterman J; Criel N
Palliat Med; 2011 Mar; 25(2):111-6. PubMed ID: 20937611
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids. Palliative Care Advisory Committee.
Guest JF; Hart WM; Cookson RF
Pharmacoeconomics; 1998 Sep; 14(3):285-97. PubMed ID: 10186467
[TBL] [Abstract][Full Text] [Related]
14. Opioid use in palliative care of children and young people with cancer.
Hewitt M; Goldman A; Collins GS; Childs M; Hain R
J Pediatr; 2008 Jan; 152(1):39-44. PubMed ID: 18154896
[TBL] [Abstract][Full Text] [Related]
15. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
16. [Nociceptive cancer pain in adult patients: statement about guidelines related to the use of antinociceptive medicine].
Binhas M; Krakowski I; Marty J
Ann Fr Anesth Reanim; 2007 Jun; 26(6):502-15. PubMed ID: 17560755
[TBL] [Abstract][Full Text] [Related]
17. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
18. Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study.
Chung CP; Dupont WD; Murray KT; Hall K; Stein CM; Ray WA
Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):48-53. PubMed ID: 30003613
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
20. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L; Hays H; Jensen NH; de Waroux BL; Bolt M; Donald R; Kalso E
BMJ; 2001 May; 322(7295):1154-8. PubMed ID: 11348910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
